Last reviewed · How we verify
Losartan/Chlorthalidone in fixed dose
Losartan blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.
Losartan blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension (essential hypertension management).
At a glance
| Generic name | Losartan/Chlorthalidone in fixed dose |
|---|---|
| Also known as | LOS/CHLORTHA |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | Angiotensin II receptor antagonist + thiazide-like diuretic combination |
| Target | Angiotensin II type 1 (AT1) receptor; sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Losartan is an angiotensin II receptor antagonist (ARB) that prevents vasoconstriction and aldosterone release, reducing blood pressure through vasodilation and decreased peripheral resistance. Chlorthalidone is a long-acting thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion of water and electrolytes. The fixed-dose combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension (essential hypertension management)
Common side effects
- Dizziness
- Hyperuricemia
- Hypokalemia
- Cough
- Fatigue
- Hyperglycemia
Key clinical trials
- Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension (PHASE3)
- Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions (PHASE1)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control (PHASE3)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: